In GBM, these neural progenitor cells may be activated to migrate and interact with high-grade astrocytomas, release certain fatty-acid ethanolamide agonists to TRPV1, reduce glioma expansion, and prolong survival by stimulating tumour-supressed TRPV1. This evidence concerns the gene TRPV1 and astrocytoma (excluding glioblastoma).